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1. Introduction
Phospholipases A2 (PLA2s; EC 3.1.1.4) comprise a
large and diverse group of interfacial enzymes which hy-
drolyze the sn-2 ester bond of 1,2-diacyl-3-sn-phosp-
hoglycerides to produce lysophospholipids and fatty
acids.1–4 In snake venom secretions, PLA2s are particu-
larly common and abundant components which play im-
portant roles in toxicity.5,6 Among the wide array of activi-
ties exerted by these proteins, neurotoxicity and myotoxi-
city are two potent actions of major clinical relevance in
snakebite envenomings.7–9 In spite of the large number of
venom PLA2s isolated, and of the considerable body of
work on their biochemical and structural characterization,
as well as on their pathological effects and other bioactivi-
ties, a thorough understanding of their mechanisms of to-
xicity has not yet been achieved. The present review focu-
ses on PLA2s endowed with myotoxic effects, present in
Viperidae snake venoms. Recent advances towards under-
standing their mechanisms of action, as well as key issues
that remain to be solved, are discussed. In order to provide
a broader context to this discussion, some general aspects
of snake venom PLA2s are briefly reviewed.
2. Snake Venom PLA2s Belong 
to Two Related, But Structurally 
Distinguishable Groups
PLA2s constitute a large superfamily of enzymes
which are widely distributed in living organisms. On the
basis of their structural and biochemical properties, these
enzymes have been classified within at least 15 groups
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Abstract
Phospholipases A2 (PLA2s) are abundant components in snake venoms, which play important toxic roles. This review
focuses on group II PLA2s endowed with myotoxic effects, present in Viperidae venoms. These PLA2s are subdivided
into catalytically-active (Asp49) PLA2s, and catalytically-inactive PLA2 homologues, the latter most frequently presen-
ting the Lys49 substitution. Both protein subgroups induce skeletal muscle necrosis, although by different mechanisms.
Current evidence indicates that phospholipid hydrolysis plays a central role in the necrotizing action of Asp49 myoto-
xins, whereas PLA2 homologues rely on the direct membrane-destabilizing actions of their cationic C-terminal region to
achieve such effect, in the absence of catalysis. Both mechanisms converge in sarcolemmal permeabilization, triggering
a series of intracellular events that lead to necrosis. Most viperid PLA2 myotoxins act only locally, but those forming he-
terodimeric complexes such as crotoxin spread to distant muscles and induce rhabdomyolysis. This divergence between
local and systemic myotoxicity might be related to differences in binding specificity to cell targets. Nevertheless, the
identity of molecular targets recognized by viperid PLA2 myotoxins remains elusive. Identification of their membrane
target(s), and a deeper understanding of the catalytic-dependent and -independent mechanisms that result in membrane
destabilization, are two crucial, but still unclarified aspects of their myotoxic action.
Keywords: Phospholipase A2, myotoxin, snake venom, myonecrosis
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(I–XV), including several subgroups.10 All of the PLA2s
found in snake venoms belong to the small (12–15 kDa),
secreted-type of enzymes, composed of 119–134 amino
acids. Those present in the venoms of Elapidae are classi-
fied within group I, whereas those found in Viperidae cor-
respond to group II. Both groups share a conserved struc-
tural fold and identical catalytic machinery, but differ in
the position of one of their seven disulfide bonds, and in
their C-terminal regions.11 Group I PLA2s present a
Cys11-Cys77 bond (numbering of Renetseder12), absent
in group II enzymes, which instead possess a Cys51-
Cys133 bond. Additionally, group I PLA2s display in their
sequence an insertion of two or three amino acids within
the region 52–65, the so-called “elapid loop”, whereas
group II enzymes present a C-terminal extension of 5–7
amino acids, absent in group I PLA2s (Fig.1).
these water-soluble enzymes to adsorb to water-insoluble
lipid interfaces in order to access their substrates.4 After
enzyme binding, phospholipid substrates need to reach
the His48-Asp99 pair at the active site slot, and conse-
quently move from their original position at the interface,
traveling about 15 Å through the “hydrophobic channel”
of these enzymes. The interfacial recognition surface of
PLA2s, or “i-face”, is of utmost importance to the specifi-
city of their actions. The final catalytic efficiency of a gi-
ven PLA2 upon a particular substrate is determined not
only by the phospholipid head group specificity of its ac-
tive site, but also by the binding properties of its interfa-
cial recognition surface. In the case of venom PLA2s en-
dowed with toxic activities, such “dual recognition” beco-
mes essential to understand the diversity and specificity of
their pharmacological effects, as will be further discussed
a) b) c)
Figure 1: Comparison of the three-dimensional structure of group I and group II snake venom phospholipases A2. Ribbon representations of (a) no-
texin (PDB: 1AE7), a group I phospholipase A2 from the elapid snake Notechis s. scutatus and (c) D49 basic PLA2 (PDB: 1VAP), a group II enzy-
me from the viperid snake Agkistrodon p. piscivorus. Disulfide bonds are shown in stick representation. Superposition of both structures in (b) il-
lustrates their overall three-dimensional structure conservation. N- and C-termini, as well as helices (H1, H2, H3) and the β-wing region are labe-
led. Distinctive features as the extended C-terminal of the group II enzymes, and the “elapid loop” region of group I enzymes, are indicated with a
dotted oval and an arrow, respectively, in (b). Adapted from Ref. 111
A growing number of three-dimensional structures
of snake venom PLA2s have been solved and made avai-
lable through the Protein Data Bank (www.rcsb.org).
Their conserved structural fold is formed by a short N-ter-
minal α-helix, followed by the “calcium-binding loop”; a
second, long α-helix, connecting to the “β-wing”; and a
third, long α-helix, ending with the C-terminal loop.11 The
catalytic network of both group I and II enzymes, formed
by residues His48, Tyr52, Tyr73, andAsp99, is also highly
conserved.3 These residues, together with those coordina-
ting the essential calcium ion cofactor (Asp49, Tyr28,
Gly30, Gly32) drive the hydrolysis of the sn-2 ester bond
of phospholipids at the water-lipid interface of micelles,
monolayers, vesicles, or membranes. The catalytic acti-
vity of PLA2s upon such aggregated forms of substrates is
markedly higher than upon monomeric, dispersed substra-
tes. Such preference is explained by the specialization of
below. Indeed, this concept has been pivotal to clarify the
long-standing paradox on the lack of correlation between
the toxic potency of venom PLA2s, and their enzymatic
activity as measured using general substrates in vitro.13,14
3. Evolutionary Convergence 
of Toxicity in Elapidae 
and Viperidae PLA2s
The structural properties shared between group I
PLA2s from elapids and group II PLA2s from viperids,
namely the conservation of their three-dimensional fold
and catalytic machinery, obviously imply a common ance-
stor in evolution. However, the existence of differences re-
garding their distinctive disulfide bonding patterns and the
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alternative presence of a C-terminal extension, or an “ela-
pid loop”, have relevant evolutionary implications when
viewed within the context of the non-toxic, group I and
group II secreted PLA2s of mammalian origin.
Snake venom toxins arose by the recruitment of few
ancestral genes coding for non-toxic proteins, which gra-
dually evolved under natural selection by duplication and
divergence, most notably in surface amino acid residues,
to acquire the ability to interfere with vital physiological
processes of prey.15–24 The evident structural similarity
between PLA2s from elapid venoms and the mammalian
pancreatic PLA2s (group I), on one hand, and between the
PLA2s from viperid venoms and mammalian synovial or
inflammatory PLA2s (group II), on the other hand, indica-
tes that at least two independent gene recruitment events
for venom gland PLA2s occurred during the evolution and
diversification of snakes.20–24 Clearly, the PLA2 genes that
were recruited into the elapid and viperid snake lineages,
respectively, had already diverged from their common an-
cestor at the time of recruitment, as they already pos-
sessed the distinctive features of group I and group II
enzymes (Fig.2). Notwithstanding these distinct structural
characteristics, both group I and II ancestral PLA2 genes
proved to be versatile enough to evolve into potent toxins,
selectively expressed in venom gland secretions. Since the
group I and group II structural scaffolds were already dif-
ferent when recruited into the venom proteomes of elapids
and viperids, respectively, and since both gene lineages
evolved from non-toxic enzymes into neurotoxic and/or
myotoxic enzymes, the acquisition of these novel toxic
activities by snake venom PLA2s should be regarded as a
case of convergent evolution (Fig.2).
A consequence of this view, in terms of understan-
ding the structure-function relationships of venom PLA2s
Figure 2: Convergent evolution of the toxic activities of snake venom phospholipases A2 (PLA2) in Elapidae and Viperidae. All PLA2s found in ela-
pid venoms belong to group I, sharing structural features with the non toxic pancreatic enzymes of mammals. Viperid PLA2s, on the other hand, be-
long to group II, and share structural features with the non toxic “inflammatory” or “synovial” PLA2s. Therefore, different ancestors were recruited
in elapids and viperids during the evolution and diversification of snakes. Both types of non toxic ancestors underwent a process of gene duplica-
tion and accelerated evolution which generated neurotoxic and/or myotoxic PLA2s, exemplifying a case of convergent evolution. 
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and their molecular mechanisms of toxicity, is that signifi-
cant differences may exist in the mode of action of elapid
and viperid toxins that exert the same toxic effect, i.e. they
do not necessarily act by using the same structural deter-
minants and mechanisms of toxicity, even if the final out-
come may be indistinguishable. Therefore, the reciprocal
extrapolation of findings between elapid and viperid
PLA2s is not warranted, and should be analyzed cau-
tiously in every case.
4. Viperidae Venom PLA2s: 
Group II Enzymes Further Diverged
into two Main Subgroups
Virtually all Viperidae venoms studied contain
PLA2s, which in some species may reach proportions as
high as 70–80% of their total proteins.25,26 Often, a single
species, or even a single individual, can express a multi-
plicity of PLA2 isoforms in its venom, a strong indication
of the duplication and divergence process that these genes
underwent during their accelerated evolution,15,16 and of
the biological relevance of their new adaptive roles.27,28
Remarkably, a further major structural subdivison exists
within the group II PLA2s of Viperidae, represented by the
classical “Asp49 PLA2s” and the “PLA2 homologues”.
The latter proteins, in contrast to the enzymatically active
PLA2s which present an invariant Asp49 in their catalytic
center, possess a number of amino acid substitutions, inc-
luding the notable replacement of Asp49 by Lys49 (or less
frequently by Ser, Arg, Gln, or Asn).29–37 As a major con-
sequence, these proteins cannot hydrolyze phospholi-
pids,38,39 and therefore are not true PLA2s sensu stricto.
Nevertheless, due to their high structural similarity with
classical Asp49 PLA2s, these proteins have been referred
to as PLA2 homologues.
28,40
Both the Asp49 PLA2s and the PLA2 homologue
subgroups of viperids conserve the distinctive features of
group II enzymes, i.e. disulfide bonding pattern and C-
terminal extension. Group II enzymes may present a va-
riety of states of oligomerization, either remaining as mo-
nomers, or forming in some cases homodimers, heterodi-
meric complexes, trimers, or larger oligomers. The va-
riable oligomerization of these proteins may have rele-
vant implications for their toxic potencies and mecha-
nisms of action.40–47 In addition to their variable quater-
nary structural organization, viperid venom PLA2s ha-
ving a wide range of isoelectric points can be found, from
acidic to highly basic proteins. As a general trend, the to-
xicity of PLA2s is associated with a more basic character
of the protein, i.e. a higher content of Lys and Arg re-
sidues in their primary structure. Many acidic PLA2s
found in these venoms do not display evident toxic pro-
perties in vivo, and for this reason may be considered to
play a merely digestive role.48,49 However, exceptions to
this general trend exist, since some acidic PLA2 have
been shown to induce important toxic effects in vivo, inc-
luding myotoxicity, albeit with a weaker potency than
their basic counterparts.50–53
The toxic group II venom PLA2s are targeted main-
ly toward the neuromuscular system in vivo, displaying
either myotoxicity alone, or a combined presynaptic neu-
rotoxic and myotoxic action.7,32,54,55 Proinflammatory and
other effects of these PLA2s have also been demonstrated
in vivo, for example, hypotensive activity.56–59 On the ot-
her hand, a number of activities of these proteins, such as
anticoagulant and platelet-modulating effects, have been
characterized in vitro, but evidence to support similar ro-
les in vivo is generally more scarce.
5. Myotoxicity of Viperid PLA2s: 
Different Pathways Lead 
to a Common Outcome
5. 1. Catalytically-active (Asp49) PLA2
Myotoxins.
Early studies on the toxic activities of snake venom
PLA2s attributed their effects to their ability to hydroly-
ze phospholipids, releasing lysophospholipids and fatty
acids, even though it was soon appreciated that toxicity
and catalytic efficiency were poorly correlated. Some
highly toxic PLA2s have very low enzymatic activity,
and conversely, a number of highly active enzymes dis-
play low toxicity, or even are non-toxic. As mentioned
before, such puzzling observations became more clear
when the interfacial binding properties of PLA2s toward
their biologically relevant substrates were considered as
a key element in their mechanisms of toxicity.13,60 The
catalytic activity of a PLA2 toxin upon “general” sub-
strates in vitro does not necessarily reflect the type and
magnitude of the catalysis that may occur when acting
upon their biologically relevant targets in vivo. Yet, cha-
racterizing the latter phenomenon has proven to be a
challenging task, with many inherent technical difficul-
ties to overcome.13,14 Nevertheless, as a general princi-
ple, it has been shown that catalytically-active viperid
PLA2s which present myotoxic activity rely upon phosp-
holipid hydrolysis to induce their necrotizing effect on
skeletal muscle tissue. When the catalytic activity of the-
se enzymes is abrogated, for example by chemical modi-
fications (most notably alkylation of His48 by p-bro-
mophenacylbromide,61 by the use of some inhibitors, or
by calcium-ion chelation), myotoxicity is drastically im-
paired, if not abolished.50,62–64 Therefore, it has been rea-
sonably concluded that enzymatic activity is necessary
for myotoxicity, either because phospholipid hydrolysis
promotes membrane instability or because the lysop-
hospholipid and fatty acid products, generated by the
phospholipid hydrolysis taking place at the surface of
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skeletal muscle fibers, play a role in the mechanism
exerted by the myotoxic Asp49 PLA2s from viperids.
Both of these products are well known to induce impor-
tant biophysical alterations in membranes, which affect
their stability.65–67 Furthermore, some studies have de-
monstrated that the myotoxic action of particular PLA2s
can be mimicked solely by their products of hydroly-
sis,51,68 a phenomenon also demonstrated in studies with
presynaptically-acting neurotoxic PLA2s.
69,70 Thus,
hydrolysis of membrane phospholipids by Asp49 PLA2s
clearly constitutes at least one mechanism that leads to
myotoxicity. In addition to this catalytic-dependent path-
way, it has been proposed that Asp49 PLA2 myotoxins
might have the ability to induce muscle damage by a ca-
talytic-independent action, perhaps in similarity to PLA2
homologues. Support to this proposal has relied on the
observation that a complete enzymatic inactivation of
these proteins, in some cases, does not completely abro-
gate their myotoxic activity, but instead a variable resi-
dual effect remains.62,71–74 While plausible, this hypothe-
sis needs to be re-evaluated in the light of more recent
findings which indicate that Asp49 PLA2 myotoxins can
be easily contaminated by Lys49 variants co-existing in
the same venom (our unpublished data). Contamination
of Lys49 myotoxins with Asp49 isoforms can be de-
tected by evaluating the enzymatic activity of the prepa-
rations, but the reciprocal situation poses a more difficult
challenge, as there is no specific functional assay to de-
tect the presence of Lys49 proteins in Asp49 PLA2 pre-
parations. More sensitive analytical techniques available
nowadays would allow to re-evaluate experiments per-
formed during the 1990’s and early 2000’s, to clarify this
relevant issue, for a more precise understanding of the
structure-function relationships in Asp49 PLA2 myoto-
xins.
5. 2. Catalytically-inactive PLA2
Homologue Myotoxins
The discovery of PLA2 homologues,
29 which exert
potent myotoxicity despite lacking the ability to hydroly-
ze phospholipids,38,39 required a new explanation for their
mode of action. A particular region near the C-terminus of
these proteins, rich in cationic and hydrophobic residues,
was first identified to have a role in membrane damage
and cytolysis, when a short synthetic peptide representing
such region was found to mimic these toxic activities.75
Subsequent studies confirmed the key role of this “toxic
site” located on the surface of PLA2 homologues,
76–88
which therefore represents a new mechanism leading to
myotoxicity, completely independent of phospholipid
hydrolysis. The final delineation of this particular “toxic
site” of PLA2 homologues is still under investigation, and
has been reviewed elsewhere.34,46,47,80,81 PLA2 homolo-
gues occur in a large number of viperid taxa, with more
than 60 proteins isolated to date. However, they are not
ubiquitous in all viperids, and, intriguingly, appear to be
absent in the venoms of some species that are phylogene-
tically very close to others that contain them.28 The evolu-
tionary emergence of PLA2 homologues is enigmatic,
considering that they originated from catalytically-active
Asp49 PLA2s, before the separation of Viperinae and Cro-
talinae lineages.28,36,37,52,89–91 However, it is clear that
myotoxicity must have been a relevant driving force for
their evolution, as all PLA2 homologues studied to date
share this activity.
5. 3. Heterodimeric (Asp49) PLA2
Myotoxins 
A third pathway towards myotoxicity is represented
by the case of heterodimeric PLA2s from viperids, such as
crotoxin and Mojave toxin, found in several species of
Crotalus,92–94 and possibly in few other viperid genera, as
recently discovered for the arboreal pitviper Bothriechis
nigroviridis.95 These strongly myotoxic and neurotoxic
molecules are composed of a non-covalently linked basic
PLA2 subunit, which is a catalytically-active Asp49 enzy-
me (subunit B), and an acidic, non-enzymatic subunit, al-
so called a “chaperone” (subunit A). Crotoxin, the para-
digmatic molecule of this group, is quite distinct from ot-
her viperid PLA2 myotoxins, since it is able to spread
systemically from its site of injection, and after reaching
its target, to dissociate the chaperone subunit from the
PLA2 subunit, which, in turn, is responsible for toxi-
city.59,96 The mode of action of the B subunit might be si-
milar to that of other catalytically-active, Asp49 PLA2s,
but the fact that crotoxin has evolved a distinct, more ela-
borate mechanism of action allows to classify this myoto-
xic and neurotoxic protein as a group of its own. In con-
trast to all other myotoxic PLA2s from viperids. which in-
duce skeletal muscle damage only nearby their site of in-
jection, crotoxin and crotoxin-like proteins induce also
systemic myotoxicity.97–99 The dichotomic presentation of
myotoxicity in viperid envenomings as either local or
systemic has been explained on the basis of the specificity
that different myotoxic PLA2s have for acceptors in musc-
le and other cell types.74 Some myotoxic PLA2s bind to
various types of cells upon injection in the tissues. Conse-
quently these toxins are likely to remain at the site of ve-
nom injection, provoking local myotoxicity, but being
unable to distribute to distant muscles. In contrast, myoto-
xic PLA2s that present higher selectivity to targets in
muscle cells, such as crotoxin and Mojave toxin, provoke
local myotoxicity at the site of injection, but are also ca-
pable of distributing to distant muscle compartments,
where they bind and affect muscle fibers, thus inducing
systemic myotoxicity which, clinically, manifests as rhab-
domyolysis.74,100
In summary, myotoxic PLA2s from viperids have
evolved at least three different strategies that lead to a
rapid skeletal muscle necrosis as the final outcome
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Figure 3: Different mechanisms for the induction of myonecrosis by viperid (group II) venom phospholipases A2 (PLA2s). The catalytically-active
Asp49 PLA2s (left) mainly rely on their enzymatic activity to hydrolyze membrane phospholipids (PL) and release fatty acids (FA) and lyso-PL
products, destabilizing membrane integrity. Some of these Asp49 PLA2s, such as crotoxin, act as a heterodimeric complex which dissociates upon
binding and releases the “chaperone” subunit, leaving the catalytic subunit free to exert its membrane-damaging action. On the other hand, the ca-
talytically-inactive PLA2 homologues (right) such as the Lys49 myotoxins, are able to interact with membranes and directly destabilize their inte-
grity, in the absence of catalysis. All of these strategies converge in the permeabilization of the sarcolemma, which initiates a stereotyped series of
common events that lead to a rapid cell death by necrosis. 
(Fig.3): (a) an ability to hydrolyze phospholipids and
generate lysophospholipid and fatty acid products wit-
hin or nearby the muscle cell membrane, either by ac-
ting as monomers or homo-oligomers, (b) by acting as
heterodimeric complexes that dissociate after binding to
their target; phospholipid hydrolysis per se, together
with the released hydrolysis products, in turn, alter the
integrity of the plasma membrane; or (c) an ability to di-
rectly affect the integrity of the muscle cell membrane
using a non-enzymatic mechanism. All three strategies
displayed by viperid PLA2 myotoxins eventually con-
verge in the permeabilization of the plasma membrane,
with catastrophic consequences for the affected muscle
fibers (Fig.3). 
6. Molecular Pathogenesis of Skeletal
Muscle Damage: What Happens
When Viperid PLA2 Myotoxins
Encounter Muscle Fibers?
6. 1. Initial Plasma Membrane Damage
The mechanisms outlined in the preceding section all
converge to a common target: the plasma cell membrane of
skeletal muscle fibers, or sarcolemma. Although the direct
binding of viperid PLA2s myotoxins has been difficult to do-
cument experimentally, due to the particulatly strong non-
specific binding properties of these toxins, the wealth of ex-
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perimental evidence clearly supports the view that sarcolem-
ma is their first site of action, and that the rest of degenerati-
ve events occurring in skeletal muscle fibers are secondary
to this primary event. However, the precise targets of PLA2s
in sarcolemma have not been identified (see section 7). Re-
gardless of the nature of sarcolemmal binding sites, the inte-
raction of myotoxic PLA2s with this membrane provokes ra-
pid and drastic alterations in structure and function, revealed
by ultrastructural evidence of membrane disruption,101–103
by rapid depolarization,94,105 by the efflux of cytosolic mar-
kers such as myoglobin, creatine kinase and lactate dehydro-
genase,101,106–108 and by an influx of Ca2+ ions.68,109,110 The
possibility of internalization of group II PLA2 myotoxins to
cause additional effects upon intracellular targets, further
extending the consequences of the initial membrane dama-
ge, has not yet been experimentally addressed.
As discussed before, the mechanism of membrane
damage is likely to involve catalytically-independent
events in the case of PLA2 homologues, and, in enzymati-
cally-active PLA2s, the hydrolysis of membrane phospho-
lipids. Catalytically-inactive PLA2 homologues, such as
Lys49 variants, are able to disrupt the integrity of membra-
nes by a process that involves the interaction of a cationic-
hydrophobic stretch of residues, located near the C-termi-
nus, with membrane phospholipids, resulting in penetra-
tion and/or disorganization of the bilayer structure.75,79,111
Whether these toxins affect the membrane by penetra-
tion112,113 or whether they “extract” membrane constituents
by a “micellar nucleation” event,114,115 or combine both
mechanisms, warrants further investigation using biophysi-
cal experimental approaches. Membrane characteristics,
such as the presence of anionic sites and cholesterol, as
well as fluidity, influence the ability of Lys49 PLA2s ho-
mologues to affect membrane structure.62,107,113 In the case
of Asp49 myotoxic PLA2s, plasma membrane damage is
associated with phospholipid hydrolysis.71,73 Hydrolysis
per se may cause membrane alterations, and may also af-
fect membrane integrity through the detergent action of the
hydrolytic products of phospholipids, i.e. lysophospholi-
pids and fatty acids.111,116 In addition, catalytically-active
myotoxic PLA2s may also present molecular determinants,
such as cationic-hydrophobic surfaces, which could allow
them to interact and disorganize bilayers independently of
enzymatic hydrolysis.62,117 Interestingly, a synergism bet-
ween Asp49 PLA2s and PLA2 homologues regarding their
membrane-permeabilizing actions has been demonstrated
in vitro, using liposomes118 or C2C12 cultures.68 This
synergism might provide an adaptive explanation for the
presence of both types of myotoxic PLA2s within a single
venom, as frequently found in viperids. 
6. 2. Intracellular Degenerative Events that
Follow Initial Sarcolemmal Damage
One of the main consequences of plasma membrane
disruption is the rapid influx of Ca2+ ions following a
steep electrochemical gradient across the sarcolemma.
This phenomenon has been documented in vivo101 and, in
greater detail, in cell culture studies.68,87,110 The conse-
quent increment in cytosolic Ca2+ concentration induces a
series of degenerative events which, very rapidly, can
bring the cell beyond the “point of no return”, i.e. to irre-
versible cell damage. The most important consequences
of this Ca2+ increment are: (a) Hypercontraction of myofi-
laments, evidenced by light and electron microscopic ob-
servations;102,119–121 such hypercontraction, in turn, may
induce further mechanical damage to the integrity of pla-
sma membrane.121 (b) Mitochondrial damage, characteri-
zed at the ultrastructural level by the appearance of high
amplitude swelling, flocculent densities, hydroxyapatite
crystals, and membrane disruption.102,103,119 It is likely that
mitochondria undergo a process of Ca2+ accumulation,
through the Ca2+ uniporter, followed by hydroxyapatite
precipitation and by the formation of flocculent densities
and the permeability transition pore.111 Such events have
drastic consequences for cell viability, owing to the key
role that this organelle has for ATP generation and cell
survival. (c) Activation of Ca2+-dependent proteinases,
such as m- and μ-calpains, which contribute to the degra-
dation of cytoskeletal components, such as desmin, titin
and α-actinin.122,123 (d) Activation of cytosolic PLA2s,
which could contribute to phospholipid hydrolysis in the
plasma membrane, as well as in the membranes of orga-
nelles such as mitochondria and sarcoplasmic reticulum,
further compromising cell viability. Interestingly, these
series of cellular alterations are common to many patholo-
gical processes associated with plasma membrane dama-
ge. Thus, regardless of the initial mechanism of sarcolem-
mal lesion, the consequent influx of Ca2+ provokes a ste-
reotyped series of degenerative events which are shared in
many pathological models, including those induced by
snake venom myotoxic PLA2s.
111
6. 3. A New Insight: the Expansion 
of Myocyte Damage by Released 
Intracellular Components
The scenario of PLA2-induced muscle damage in-
volves an additional aspect just recently described: the de-
leterious actions of ions and molecules released from da-
maged cells. The disruption of the integrity of plasma
membrane provokes the efflux of cytosolic components.
Among them, K+ and ATP diffuse in the vicinity of dama-
ged muscle fibers, reaching other fibers not yet directly
affected by the myotoxins. K+ is known to induce pain, by
acting on afferent neurons, and has been proposed to play
a role in the acute pain associated with the action of myo-
toxic PLA2s.
124 ATP, in turn, is likely to amplify the effect
of myotoxins by acting as a “danger signal”, binding to
ATP-gated purinergic muscle channels in the plasma
membrane, and provoking a Ca+2 influx which may cause
deleterious cell events in the neighborhood of myotoxin-
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damaged cells. The reduction of increments in cytosolic
Ca2+ concentration and of cell damage observed when
myotubes in culture are exposed to myotoxins in the pre-
sence of apyrase, which quenches ATP, or of oxidized
ATP, which blocks the purinergic receptors, supports the
contention that ATP released from myotoxin-damaged
myotubes diffuses and provokes Ca2+ entry and damage in
myotubes not directly affected by the toxin.124 These fin-
dings introduce a novel perspective to understand the
mechanism of action of myotoxic PLA2s whereby the di-
rect cytotoxic action of myotoxins in the plasma membra-
ne occurs concomitantly with an indirect action based on
the effect of released ATP in neighboring muscle cells.
The possible therapeutic implications of these findings are
obvious, since it can be hypothesized that the blockade of
purinergic channels may reduce the extent of muscle da-
mage induced by myotoxic PLA2s. 
7. Acceptors: Key Missing Elements 
in Our Understanding 
of the Mechanisms of Myotoxicity 
in Viperid PLA2s
In order to induce myotoxicity, viperid PLA2s must
interact with particular components on the surface of
muscle fibers whose identities, until now, have remained
elusive. Such molecular targets or “acceptor” sites should
be more abundant on skeletal muscle fibers than on other
cell types, as suggested by several lines of evidence: (a)
Histological and ultrastructural evaluations of muscles
where viperid PLA2s have been injected reveal wides-
pread myonecrosis, whereas other cell types in the vici-
nity of the destroyed fibers appear to be spared from da-
mage, as judged by morphological criteria;102 (b) In vitro,
myotoxic PLA2s are able to cause a rapid cytolysis of all
types of cells tested so far, excluding erythrocytes, alt-
hough showing a moderately higher activity upon myoge-
nic cell lines;107,125,126 (c) During the in vitro differentia-
tion of myogenic cell lines, a specific increment occurs in
their susceptibility to viperid PLA2s, i.e. myotubes beco-
me more sensitive than their precursor myoblasts.68,127
Notwithstanding, efforts made so far to identify the rele-
vant molecular target(s) of these myotoxins have been in-
conclusive.
Myotoxic PLA2s from viperids are proteins with
highly basic isoelectric points, which a priori would sug-
gest that they might interact with negatively charged
membrane targets. Experiments using different types of li-
posomes evidenced the ability of these toxins to disrupt
their integrity causing release of entrapped markers, and
this effect was demonstrated to be significantly higher
when negatively charged phospholipids are present in the
liposome composition.62,112,128,129 Liposome disruption by
viperid PLA2s demonstrates that these myotoxins are ca-
pable of drastically altering phospholipid membrane bila-
yers without the requirement of proteins, but this does not
exclude the possibility that membrane proteins on the sar-
colemma may be important for the specificity and effi-
ciency of their myotoxic effect, especially considering
that negatively charged phospholipids are very scarce on
the outer layer of cell membranes. Moreover, it is also
possible that molecules other than proteins or phospholi-
pids could play the role of membrane acceptors for these
viperid myotoxins. Only few attempts to explore such
possibilities have been reported in the literature. In vitro
treatment of cells with tunicamycin to inhibit overall N-
linked glycosylations, or with neuraminidase to hydrolyze
the negatively charged N-acetylneuraminic acid on their
surface, did not affect the ability of a Lys49 myotoxin to
exert its cytolytic action.107 Target cells have also been
treated in vitro to decrease their heparan sulfate proteogly-
can, another negatively-charged surface component, eit-
her by enzymatic hydrolysis, or by inhibiting its sulfation
step during synthesis using sodium chlorate. Neither of
these treatments, nor the use of a cell mutant devoid of he-
paran sulfate, had an influence on the cytolytic action of a
Lys49 myotoxin.130
Protein acceptors have been identified for secreted
PLA2s, both of mammalian
131 and snake venom132–140 ori-
gins. In the case of viperid PLA2 myotoxins, only crotoxin
has been found to interact with a membrane protein of
45–48 kDa, albeit in relation to its neurotoxic actions us-
ing membrane preparations from guinea pig brain or Tor-
pedo marmorata electric organ.132,138 However, thus far no
evidence has been reported to support the involvement of
specific protein acceptors in the mechanism of membrane
damage induced by viperid PLA2 myotoxins. An exciting
prospect emerged by the finding that the PLA2 homologue
myotoxins bind with high affinity to the vascular endothe-
lial growth factor (VEGF) receptor-2, or KDR,141 and by
the subsequent mapping of their interaction site at the sa-
me region involved in toxicity, that is, the cationic C-ter-
minal region 115–129.142 However, it has not been estab-
lished whether such interaction is functionally relevant to
the myotoxic mechanism exerted by Lys49 PLA2 homolo-
gues. Our preliminary findings suggest that VEGF recep-
tor-2 is not required for the functional expression of toxic
activity by these proteins (unpublished data). Asp49 myo-
toxic PLA2s, on the other hand, do not bind to this particu-
lar receptor.142
Some experimental observations suggest the possi-
bility that a protein acceptor may not be required for the
toxic mechanism of viperid PLA2s. For example, a
synthetic peptide representing the C-terminal region of a
Lys49 myotoxin reproduced its toxic effects in vitro as
well as in vivo, not only in its normal L-configuration, but
also when synthesized with all-D amino acids,83 a finding
that would argue against an interaction with a configura-
tion-dependent molecular acceptor such as a protein. Ot-
her lines of evidence suggest that membrane anionic
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phospholipids could constitute relevant binding sites for
viperid PLA2 myotoxins. Enrichment of the outer mem-
brane leaflet of erythrocytes with phosphatidylserine or
phosphatidic acid rendered these cells susceptible to lysis,
whilst they are normally insensitive to the cytolytic action
of both Asp49 and Lys49 myotoxins.143
Disruption of membrane lipid rafts by the use of
cyclodextrin in cultured myogenic cells did not prevent
the cytolytic activity exerted by these two types of
PLA2s, ruling out their possible role as acceptors.
113
Whatever the identity of the unknown acceptor(s) for vi-
perid PLA2s, a recent study provided evidence that it is
likely to be coupled to a rapid signaling mechanism for
intracellular calcium release, a phenomenon that prece-
des the massive influx of this ion from the extracellular
medium.68 The fact that group II PLA2 myotoxins have
such a broad range of cytolytic specificity in vitro, inclu-
ding not only many eukaryotic cell types but also a va-
riety of bacteria,84,85 suggests that their requirements for
binding sites on membranes might not be too stringent,
and perhaps do not involve a highly specific protein ac-
ceptor. In support of this speculation, the doses at which
group II PLA2 toxins induce myonecrosis in experimen-
tal animals are relatively high, when compared to some
highly potent group I PLA2s endowed with both myoto-
xic and neurotoxic effects,121 or to the systemically ac-
ting heterodimeric PLA2s such as the crotoxin com-
plex.99 The observed selectivity of viperid PLA2s toward
skeletal muscle fibers, when injected locally, might sim-
ply be a reflection of the highly disparate proportion of
sarcolemma available, in comparison to membranes of
other cell types.
8. The Action of Viperid Myotoxic
PLA2s in the Clinical Context
The clinical presentation of myotoxicity in the vast
majority of viperid snakebite envenomings is characteri-
zed by prominent local myonecrosis.144–146 In these cases,
the deleterious action of myotoxic PLA2s occurs conco-
mitantly with drastic alterations induced by hemorrhagic
metalloproteinases in the microvasculature, generating an
ischemic scenario which further contributes to muscle da-
mage.147 Moreover, alterations in intramuscular ner-
ves148,149 add to this complex picture. As a consequence of
these alterations, the process of muscle regeneration is im-
paired,149 leaving the patients with permanent sequelae.145
Thus, in these cases, viperid myotoxic PLA2s contribute
to local pathological damage, but do not generate syste-
mic myotoxicity. In contrast, envenomings by the rattle-
snakes C. d. terrificus and some populations of C. scutula-
tus are characterized by local and systemic myotoxicity,
evidenced by very high increments in plasma CK acti-
vity.150 This is likely to be a consequence of the systemic
action of the dimeric PLA2s crotoxin and Mojave toxin on
skeletal muscles. In these cases, rhabdomyolysis results in
myoglobin accumulation in the kidneys, which may result
in acute renal failure, a severe complication in these enve-
nomings.150
9. Future Directions
A growing body of information, gathered after the
isolation and characterization of a number of viperid sna-
ke venom PLA2s endowed with myotoxic activity, has
provided significant insights into their structure and its re-
lationships to the functional mechanisms leading to skele-
tal muscle necrosis. It has been clearly established that
these toxins affect muscle cells by catalytically-dependent
and -independent mechanisms, and that disruption of the
integrity of skeletal muscle sarcolemma constitutes the
first step in their mode of action, followed by a stereoty-
ped series of intracellular degenerative events mostly as-
sociated with increments in cytosolyc Ca2+ concentration.
However, a thorough understanding of their modes of ac-
tion has been hampered by the lack of knowledge on their
target molecules on the surface of skeletal muscle fibers.
Further efforts are needed to identify such targets, to cha-
racterize their molecular interactions with the toxins, and
to address the details of the mechanisms that lead to sar-
colemma permeabilization, the primary event leading to
myonecrosis.
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Povzetek
Fosfolipaze A2 (PLA2) so bogato zastopane komponente ka~jih strupov, ki igrajo pomembno vlogo pri izra`anju tok-
si~nosti le-teh. Pregledni ~lanek se osredoto~a na PLA2 iz skupine II, ki jih najdemo v strupih viperid in, ki izra`ajo
miotoksi~ne u~inke. Te PLA2 razdelimo na katalitsko aktivne (Asp49) PLA2 in na katalitsko neaktivne PLA2 homologe.
Slednji imajo najpogosteje na polo`aju 49 Lys. Obe skupini PLA2 izzoveta nekrozo skeletnih mi{ic, a po razli~nih me-
hanizmih. Rezultati ka`ejo, da hidroliza fosfolipidov igra osrednjo vlogo pri nekroznem delovanju Asp49 miotoksinov,
medtem ko miotoksi~nost PLA2 homologov temelji na neposredni destabilizaciji membrane s kationskim predelom na
C-koncu teh molekul. Oba na~ina delovanja rezultirata v permeabilizaciji sarkoleme, kar spro`i vrsto znotraj celi~nih
dogodkov, ki vodijo v nekrozo celice. Ve~ina viperidnih PLA2 miotoksinov deluje lokalno, a tisti, ki tvorijo heterodi-
merne komplekse, na primer krotoksin, se raz{irijo do oddaljenih mi{ic in izzovejo rabdomiolizo. Razlika med lokalno
in sistemsko miotoksi~nostjo PLA2 bi lahko izhajala iz razlik v vezavni specifi~nosti teh molekul za celi~ne tar~e. Iden-
titeta celi~nih tar~, na katere bi se vezali viperidni PLA2 miotoksini je {e neznana. Opis membranskih receptorjev za
miotoksi~ne PLA2 in natan~no razumevanje od encimske aktivnosti-odvisnega in neodvisnega mehanizma delovanja
PLA2, ki vodi do destabilizacije membrane, sta dva pomembna, a {e vedno nepojasnjena vidika miotoksi~nega delova-
nja teh molekul. 
